| 3rd Aug 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 3rd Aug 2026 3:00 pm |
RNS |
Total Voting Rights |
| 31st Jul 2026 7:30 am |
RNS |
Datroway approved in EU for TNBC |
| 27th Jul 2026 7:10 am |
RNS |
Update on Ultomiris Phase III trial in HSCT-TMA |
| 27th Jul 2026 7:05 am |
RNS |
Sone-Ve improved survival in gastric cancers |
| 27th Jul 2026 7:00 am |
RNS |
Half-year Financial Report |
| 23rd Jul 2026 7:00 am |
RNS |
Etcamah approved in the EU for ER+ breast cancer |
| 14th Jul 2026 7:00 am |
RNS |
AstraZeneca licenses novel EGFR inhibitor |
| 9th Jul 2026 7:00 am |
RNS |
Update on CARDIO-TTRansform Phase III trial |
| 1st Jul 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 1st Jul 2026 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jun 2026 7:30 am |
RNS |
Enhertu approved in EU for HER2+ solid tumours |
| 29th Jun 2026 7:00 am |
RNS |
Datroway recommended for approval in EU for TNBC |
| 15th Jun 2026 7:00 am |
RNS |
Truqap approved in US for prostate cancer |
| 1st Jun 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 1st Jun 2026 3:00 pm |
RNS |
Total Voting Rights |
| 29th May 2026 7:00 am |
RNS |
Imfinzi approved in US for early bladder cancer |
| 27th May 2026 7:00 am |
RNS |
US FDA decision date on camizestrant extended |
| 26th May 2026 7:00 am |
RNS |
Enhertu recommended in EU for HER2+ solid tumours |
| 26th May 2026 7:00 am |
RNS |
Camizestrant recommended for breast cancer in EU |
| 26th May 2026 7:00 am |
RNS |
Datroway approved in US for 1L triple-negative BC |
| 18th May 2026 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 18th May 2026 7:05 am |
RNS |
Enhertu approved in two HER2+ early BC settings |
| 18th May 2026 7:00 am |
RNS |
Baxfendy approved in the US for hypertension |
| 14th May 2026 7:00 am |
RNS |
Imfinzi + EV improves EFS & OS in bladder cancer |
| 1st May 2026 3:00 pm |
RNS |
Total Voting Rights and Admission of Shares |
| 1st May 2026 7:05 am |
RNS |
FDA ODAC vote on camizestrant in breast cancer |
| 1st May 2026 7:00 am |
RNS |
FDA ODAC recommends Truqap in prostate cancer |
| 29th Apr 2026 7:00 am |
RNS |
1st Quarter Results |
| 28th Apr 2026 7:00 am |
RNS |
Breztri approved in the US for asthma |
| 27th Apr 2026 7:00 am |
RNS |
Saphnelo self-administration approved in the US |
| 23rd Apr 2026 7:00 am |
RNS |
Directorate change |
| 21st Apr 2026 7:00 am |
RNS |
I CAN PhIII interim analysis met primary endpoint |
| 20th Apr 2026 7:00 am |
RNS |
Third tozorakimab positive Phase III in COPD |
| 9th Apr 2026 5:15 pm |
RNS |
Result of AGM |
| 2nd Apr 2026 7:00 am |
RNS |
Imfinzi+Imjudo improves PFS in early liver cancer |
| 1st Apr 2026 3:00 pm |
RNS |
Total Voting Rights and Admission of Shares |
| 31st Mar 2026 7:00 am |
RNS |
Efzimfotase alfa Ph3 program show positive results |
| 27th Mar 2026 7:00 am |
RNS |
Tozorakimab met OBERON/TITANIA primary endpoints |
| 20th Mar 2026 11:00 am |
RNS |
Notification of Admission of Shares |
